Key result
Plasma levels of angiopoietin-2 correlated independently with the severity of arterial stiffness assessed by pulse wave velocity in patients with chronic kidney disease.
Why the study?
Does angiopoietin-2 correlate with arterial stiffness in CKD, and does its blockade attenuate vascular inflammation and fibrosis?
Population
416 patients with chronic kidney disease, and mice subjected to 5/6 subtotal nephrectomy or unilateral…
Comparison
Angiopoietin-2 blockade (in mouse model) vs Control/vehicle (implied in mouse model)
Design
Preclinical
Authors
Loading...
Angiopoietin-2 may link to vascular calcification in CKD; hypothesis-generating, prospective studies needed before clinical relevance.
Cohort (n=416)
Does angiopoietin-2 correlate with arterial stiffness in CKD, and does its blockade attenuate vascular inflammation and fibrosis?
Angiopoietin-2 links kidney fibrosis to arterial stiffness, suggesting its blockade could be a novel therapeutic target for cardiovascular disease in CKD.
Chang et al. (2014) conducted a cohort in Chronic Kidney Disease (n=416). Angiopoietin-2 was evaluated on Severity of arterial stiffness assessed by pulse wave velocity. Plasma levels of angiopoietin-2 correlated independently with the severity of arterial stiffness assessed by pulse wave velocity in patients with chronic kidney disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: